logo
Share SHARE
FONT-SIZE Plus   Neg

AVI BioPharma Gets FDA Approval To Proceed With AVI-7288 To Treat Marburg Virus

AVI BioPharma, Inc. (AVII) Tuesday announced that the U.S Food and Drug Administration, or the FDA, has granted approval to the company to proceed with a single oligomer, AVI-7288, in studies in both humans and non-human primates to support the safety and efficacy of post-exposure prophylaxis against Marburg virus infection.

The company stated that AVI-7288 is one of two components that make up AVI-6003.

The company further added that it will proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies planned to characterize the safety, tolerability and pharmacokinetics of multiple doses of the drug in healthy adult volunteers.

"While we have not seen any toxicity in humans to date with AVI-6003, by removing AVI-7287 we have a simpler development path and may improve the therapeutic window by evaluating a single action agent," said Chris Garabedian, president and CEO of AVI BioPharma. "We are pleased to be able to explore this single oligomer as a potentially safe and effective treatment against this lethal hemorrhagic fever virus."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Heading into a quiet week that precedes the final FOMC meeting of the year, the economic momentum remains strong. Data releases from the just concluded week makes it tough for the central bank to pass up an interest rate hike. However, will the Fed risk a backlash in a transition period on the political... AutoZone, Inc., an automotive replacement parts retailer, reported Tuesday higher profit in its first quarter with increased net sales and domestic store sales. Earnings per share topped analysts' estimates, while top line missed the view. In the pre-market activity on the NYSE, AutoZone shares were gaining 1.10 percent. The Justice Department, in the antitrust trial against the proposed Aetna- Humana Merger, argued that the merger would harm senior citizens who buy private Medicare plans. The U.S. Department of Justice stated that the merger would also harm consumers who buy plans on Affordable Care Act marketplaces, reports said. However, healthcare insurers Aetna And Humana defended their proposed merger..
comments powered by Disqus
Follow RTT